U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer
Harpreet Singh, Richard Pazdur(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xianhua Cao(United States Food and Drug Administration), Kimberly Barnett-Ringgold(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Joyce Cheng(United States Food and Drug Administration), Pamela Balcazar(United States Food and Drug Administration), William F. Pierce(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Paul G. Kluetz(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Nan Zheng(United States Food and Drug Administration), Qi Liu(United States Food and Drug Administration), Jingyu Yu(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Amanda J. Walker(National Cancer Institute), Selena Daniels(United States Food and Drug Administration)
Cited by 98
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k